Arrowhead's 750-Patient Heart Data: A $12B Test
Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, with no approved products and negative operating cash
Arrowhead's 750-Patient Heart Data: A $12B Test
NEW YORK, August 30 —
Arrowhead Pharmaceuticals, Inc. (ARWR) carries a $12 billion market cap on zero approved products, sustained by partner milestone payments that register 100% gross margins but consume $59M in annual operating cash. A 750-patient cardiovascular dataset at an upcoming late-breaking conference is the next referendum on whether that price tag holds.
- TTM revenue grew 171% to $670M at 100% gross margin, all milestone and licensing fees from GSK, Takeda, Amgen, Sarepta.
- Most recent quarter EPS: -$1.36, missing the -$1.23 consensus by 10.5%; operating cash flow runs at -$59M trailing.
- Two directors sold $1.19M in shares on August 18; no insider purchases in the past 90 days.
The Revenue Illusion
Arrowhead's RNAi pipeline, Phase 3 programs Plozasiran (targeting apolipoprotein C-III) and Zodasiran (targeting angiopoietin-like protein 3) for cardiovascular disease, has yet to generate a dollar of product sales. The 171% surge in TTM revenue to $670M reflects milestone and licensing payments from GSK, Takeda, Amgen, and Sarepta, which arrive episodically and vanish when deals lapse or trials fail. The EPS history captures the lumpiness: a 160.5% beat three quarters ago, consistent with a large milestone payment, followed by a 10.5% miss last quarter. A DCF calculator applied to this income statement would struggle to find a steady-state cash flow to discount, because there isn't one yet.
The Director Signal
On August 18, two Arrowhead directors sold shares in the open market, per Form 4 filings. Michael S. Perry offloaded 11,600 shares at $87.30 for $1.01M; Adeoye Y. Olukotun sold 2,000 shares at $86.96 for $173,920. Together, $1.19M exited with no offsetting insider purchases across 90 days, against insider ownership of 3.7% of shares outstanding. The stock had posted what one Yahoo Finance report described as a 398% run. Directors selling ahead of a conference presentation that will determine near-term valuation trajectory, rather than after a positive binary event, is a pattern that merits attention alongside the clinical data itself.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ARWR | $12.0B | n/a | +230.6% |
| ALNY | $31.7B | 18.8x | -47.0% |
| IONS | $10.1B | n/a | +6.2% |
| AXSM | $10.4B | 39.5x | +61.2% |
| ACAD | $5.0B | 32.7x | +13.3% |
| SRPT | $2.2B | 8.1x | +14.9% |
What the Data Must Deliver
The analyst consensus of $110.18-30% above the $84.91 current price, implies pipeline validation that hasn't arrived. Cash at $1.60B against $1.38B in debt supports the balance sheet through multiple development cycles, but negative operating cash flow narrows the timeline for prolonged delay. Short interest at 9.1% of float signals real skepticism from the other side of the trade. The cardiovascular conference presentation across approximately 750 participants in the Plozasiran and Zodasiran programs is the nearest binary checkpoint; if the data disappoints, the milestone revenue model loses its forward rationale. Run the free Arrowhead Pharmaceuticals, Inc. deep-dive → to track how the clinical read-out lands against the consensus gap.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why is Arrowhead's revenue growing with no products?
Arrowhead's 171% TTM revenue growth to $670M reflects milestone and licensing payments from GSK, Takeda, Amgen, and Sarepta, which carry 100% gross margins but arrive episodically. No Arrowhead drug has received regulatory approval, meaning no product sales underlie the figure. The lumpiness shows in EPS history: a 160.5% beat three quarters ago followed by a 10.5% miss last quarter.
What are Plozasiran and Zodasiran?
Plozasiran targets apolipoprotein C-III and Zodasiran targets angiopoietin-like protein 3, both Phase 3 RNAi programs for cardiovascular disease. The combined dataset across approximately 750 participants is the focus of an upcoming late-breaking conference presentation. These are Arrowhead's lead pipeline assets and the primary forward rationale for the milestone revenue model.
What did Arrowhead directors do ahead of the conference?
On August 18, two directors sold shares totaling $1.19M in open-market transactions per Form 4 filings. Michael S. Perry sold 11,600 shares at $87.30 for approximately $1.01M, and Adeoye Y. Olukotun sold 2,000 shares at $86.96 for $173,920. No insider purchases occurred in the prior 90 days, against insider ownership of 3.7% of shares outstanding.
What is the analyst price target for Arrowhead?
The analyst consensus stands at $110.18, approximately 30% above the $84.91 current price. That gap implies pipeline validation that has not yet arrived. Short interest at 9.1% of float indicates meaningful skepticism on the other side of the trade.
Does Arrowhead have enough cash to weather a clinical delay?
Arrowhead holds $1.60B in cash against $1.38B in debt, which the article describes as supporting the balance sheet through multiple development cycles. However, operating cash flow runs at negative $59M trailing, which the article notes narrows the timeline for prolonged delay. The cardiovascular conference presentation is characterized as the nearest binary checkpoint.
Arrowhead Pharmaceuticals is set to present cardiovascular studies in approximately 750 participants at a late-breaking medical conference — a binary catalyst for a company whose $12 billion market cap rests entirely on pipeline outcomes rather than product revenue. The most recent quarter missed EPS estimates by 10.5% and operating cash flow is negative, raising the question of what the data must deliver to justify current analyst targets.